TICKERNERD
Menu
MDMDHealthcare · Medical Care Facilities

MD Stock Forecast: Pediatrix Medical Group, Inc. Price Predictions for 2026-2027

Last close, 3 Sept 2026
$27
+0.07% on the day

The 7 Wall Street analysts covering Pediatrix Medical Group, Inc. hold a median 12-month price target of $28 — +4.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 99 of 100 as at 2 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$2.2B
Ticker Nerd rank
99 / 100
Median analyst target
$28
Analysts covering
7
Revenue$487.8M+4.0% y/y
Operating income$65.4M
Net income$39.8M
Free cash flow$123.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+0.3%
1M
+2.4%
YTD
+25.7%
1Y
+61.8%
From 52W high
−1.9%
From 52W low
+70.1%
$16
$27
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

MD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Pediatrix Medical Group, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 2 Sept 2026
99 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
98
Value
97
Issuance
94
Quality
90
Volatility
88
Revisions
78
Accruals
66
Growth
56
Size
35

Momentum (98): The shares have been drifting up relative to others.

Growth (56): Sales and profits are flat, shrinking, or growing more slowly than they were.

Size (35): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$16$18$20$22$24$26$28Oct 25Jan 26Apr 26Jul 26MDHigh $28Median $28Low $21

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
1 Buy6 Hold0 Sell
Low $21Median $28High $28

The green dot is the last close — the median target sits +4.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
19 Aug 2026JefferiesDowngradeHold$27 → $28
6 Aug 2026UBSMaintainsNeutral$25 → $28
6 Aug 2026UBSMaintainsNeutral—
14 July 2026Truist SecuritiesMaintainsHold$23 → $28
14 July 2026Truist SecuritiesMaintainsHold—
12 May 2026UBSMaintainsNeutral—
13 Apr 2026Truist SecuritiesMaintainsHold—
24 Feb 2026UBSMaintainsNeutral—
20 Feb 2026Truist SecuritiesMaintainsHold—
10 Nov 2025Truist SecuritiesMaintainsHold—
5 Nov 2025UBSMaintainsNeutral—
5 Sept 2025Leerink PartnersMaintainsMarket Perform—
14 Aug 2025UBSMaintainsNeutral—
12 May 2025UBSMaintainsNeutral—
8 May 2025MacquarieMaintainsOutperform—
11 Apr 2025Truist SecuritiesMaintainsHold—
21 Feb 2025Truist SecuritiesMaintainsHold—
21 Feb 2025UBSMaintainsNeutral—
6 Jan 2025Truist SecuritiesMaintainsHold—
16 Dec 2024MacquarieInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

MD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 3 Sept 2026, Pediatrix Medical Group, Inc. returned +61.8% against +21.4% for the S&P 500, dividends included.

MD vs S&P 500, last 12 monthsTotal return, rebased to 100
100120140160Oct 25Jan 26Apr 26Jul 26MDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+3.2%
Analysts raising
5
Analysts cutting
0
Fundamentals

Pediatrix Medical Group, Inc. (MD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
12.5×

Cheaper than 52% of US stocks

Price / sales
1.1×

Cheaper than 68% of US stocks

Price / book
2.4×

Cheaper than 41% of US stocks

EV / EBITDA
8.8×

Cheaper than 43% of US stocks

Growth & margins
Revenue growth (YoY)
4.0%

Higher than 36% of US stocks

Earnings growth (YoY)
1.5%

Higher than 37% of US stocks

Gross margin
27.2%

Higher than 31% of US stocks

Operating margin
13.4%

Higher than 70% of US stocks

Net margin
9.0%

Higher than 68% of US stocks

Returns & dividend
Return on equity
20.4%

Higher than 81% of US stocks

Return on assets
7.1%

Higher than 85% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Pediatrix Medical Group, Inc. (MD) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Pediatrix Medical Group, Inc. has a market value of $2.2B and an enterprise value of $2.3B.

  • Revenue in the twelve months to 30 June 2026: $2.0B. The latest quarter grew 4.0% year on year.

  • Net income over the same four quarters: $174.8M, a 9.0% net margin.

  • Diluted earnings per share, trailing twelve months: $2.09.

  • Free cash flow in the twelve months to 30 June 2026: $228.6M.

  • Pediatrix Medical Group, Inc. spent $149.1M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 81.2M.

  • Trailing P/E: 12.5×; forward P/E: 10.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Pediatrix Medical Group, Inc. employs 4,280 people — $456K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 3 Sept 2026

Data provided by Twelve Data

Peers

MD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Care Facilities
CompanyMarket capTKN rank
MDPediatrix Medical Group, Inc.$2.2B
99
ADUSAddus HomeCare Corp.$2.2B
96
GRDNGuardian Pharmacy Services, Inc.$2.5B
81
ASTHAstrana Health, Inc.$1.9B
65
ACHCAcadia Healthcare Co., Inc.$2.6B
52
SGRYSurgery Partners, Inc.$1.8B
48
SNDASonida Senior Living, Inc.$1.8B
27

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Pediatrix Medical Group, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MD news & analysis

Pediatrix Medical Group (MD) Up 3.4% Since Last Earnings Report: Can It Continue?

Zacks Investment Research · 3 Sept 2026neutral

Pediatrix Medical Group reported earnings 30 days ago, and its stock has risen 3.4% since that earnings release. The news item examines whether the stock can continue its current trajectory.

Why it matters — A Pediatrix watcher would care because the report assesses the stock's performance since the last earnings announcement and signals potential momentum for the company.

Pediatrix Medical Group (MD) is a Top-Ranked Growth Stock: Should You Buy?

Zacks Investment Research · 1 Sept 2026positive

Zacks Investment Research highlights Pediatrix Medical Group (MD) as a top-ranked growth stock based on its Style Scores, which help investors identify highly rated stocks by investing style. The article explains why investors should take advantage of this tool.

Why it matters — A top-ranked growth-stock designation from Zacks could increase investor attention and interest in Pediatrix Medical Group.

Here's Why Pediatrix Medical Group (MD) is a Strong Momentum Stock

Zacks Investment Research · 20 Aug 2026positive

Zacks Investment Research highlighted Pediatrix Medical Group (MD) as a strong momentum stock, citing its Zacks Style Scores as a way to identify market-beating stocks. The article positions MD as one such stock benefiting from momentum-based screening.

Why it matters — A positive momentum designation from Zacks could draw investor attention to Pediatrix Medical Group's stock performance.

Here's Why Pediatrix Medical Can Be a Smart Addition to Your Portfolio

Zacks Investment Research · 13 Aug 2026positive

Zacks Investment Research published an article titled "Here's Why Pediatrix Medical Can Be a Smart Addition to Your Portfolio," highlighting that stronger cash collections, a favorable payer mix, acquisitions, and its telehybrid care model support the company's growth prospects.

Why it matters — MD watchers would care because the report points to operational and strategic strengths, including cash collections, payer mix, acquisitions, and telehybrid care, as factors supporting Pediatrix's growth outlook.

Here's Why Pediatrix Medical Group (MD) is a Strong Growth Stock

Zacks Investment Research · 12 Aug 2026positive

Zacks Investment Research published an article titled "Here's Why Pediatrix Medical Group (MD) is a Strong Growth Stock," which promotes the use of the Zacks Style Scores to identify strong, market-beating stocks. The piece highlights Pediatrix Medical Group as such a growth stock.

Why it matters — This item suggests that Zacks' analysis identifies Pediatrix Medical Group as a strong growth stock, which is relevant to investors tracking the company's positioning.

FAQ

Frequently asked questions about MD stock

What is the MD stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Pediatrix Medical Group, Inc. have a median 12-month price target of $28, with estimates ranging from $21 to $28. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MD stock a buy right now?

Of the 7 analysts covering Pediatrix Medical Group, Inc., 1 rate it a Buy, 6 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Pediatrix Medical Group, Inc. 99 out of 100 across roughly 4,600 US stocks as at 2 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MD?

As at 2 Sept 2026, Pediatrix Medical Group, Inc. ranks 99 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (98 of 100).

Will MD stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +4.2% from the last close, and Ticker Nerd's factor model ranks Pediatrix Medical Group, Inc. 99 out of 100 as at 2 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MD stock forecast for 2030?

No analyst covering Pediatrix Medical Group, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $21 to $28 over the next 12 months.

How has MD stock performed over the past year?

Pediatrix Medical Group, Inc. returned +61.8% over the 12 months to 3 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Pediatrix Medical Group, Inc. do?

Pediatrix Medical Group Inc. is a physician services company focused on newborn, maternal-fetal, and pediatric subspecialty care.

What is the latest news on MD?

The most recent item we track (Zacks Investment Research, 3 Sept 2026): "Pediatrix Medical Group (MD) Up 3.4% Since Last Earnings Report: Can It Continue?". Pediatrix Medical Group reported earnings 30 days ago, and its stock has risen 3.4% since that earnings release. The news item examines whether the stock can continue its current trajectory.

Company

About Pediatrix Medical Group, Inc.

Pediatrix Medical Group Inc. is a physician services company focused on newborn, maternal-fetal, and pediatric subspecialty care. It provides hospital-based and office-based clinical services for premature and medically complex infants, expectant mothers, and children requiring specialized treatment. The company’s care network includes neonatologists, maternal-fetal medicine specialists, pediatric subspecialists, nurse practitioners, certified nurse midwives, sonographers, and genetic counselors. Pediatrix Medical Group also supports hospitals and health systems with clinical staffing and related physician-led service lines across neonatal intensive care, women’s health, pediatric cardiology, pediatric critical care, pediatric emergency medicine, and anesthesia care. Headquartered in Sunrise, Florida, Pediatrix Medical Group plays an important role in delivering specialized care in high-acuity settings where coordinated expertise and continuity of treatment are essential.

CEO Mr. Mark S. Ordan · 4,280 employees · United States · https://www.pediatrix.com